Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

by Morschhauser, Franck , Kwong, Yok-Lam , Müller, Antonia M.S , Dreyling, Martin , Bachy, Emmanuel , Masood, Aisha , Holte, Harald , del Corral, Christopher , Degtyarev, Evgeny , Bishop, Michael R , Le Gouill, Steven , Kersten, Marie J , Kharfan-Dabaja, Mohamed , Greil, Richard , Chan, Esther H.L , Martinez-Lopez, Joaquin , Bond, David , Hamad, Nada , Sureda, Anna , Barba, Pere , Rabitsch, Werner , Kato, Koji , Borchmann, Peter , Awasthi, Rakesh , Westin, Jason R , Janz, Martin , Harigae, Hideo , McSweeney, Peter , Santoro, Armando , Minnema, Monique C , Thieblemont, Catherine , Maziarz, Richard T , McGuirk, Joseph P , Andreola, Giovanna , Flinn, Ian , Schuster, Stephen J , Andreadis, Charalambos , Newsome, Simon , Jäger, Ulrich , Dickinson, Michael , Purtill, Duncan

in Adult / Aged / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Autografts / B-cell lymphoma / Bone marrow / Bone Marrow Transplantation / CD19 antigen / Cell therapy / Chemotherapy / Chimeric antigen receptors / Combined Modality Therapy / Female / Genetics / Genetics General / Hematology / Hematopoietic Stem Cell Transplantation / Humans / Immunotherapy, Adoptive / Leukapheresis / Leukemia / Life Sciences / Lymphocytes B / Lymphocytes T / Lymphoma / Lymphoma, Large B-Cell, Diffuse - drug therapy / Lymphoma, Large B-Cell, Diffuse - mortality / Lymphoma, Large B-Cell, Diffuse - therapy / Male / Medical prognosis / Middle Aged / Non-Hodgkin's lymphoma / Oncology / Patients / Progression-Free Survival / Receptors, Antigen, T-Cell - therapeutic use / Receptors, Chimeric Antigen - antagonists & inhibitors / Salvage Therapy / Severe acute respiratory syndrome coronavirus 2 / Stem cell transplantation / Tomography / Transplantation, Autologous / Treatments in Oncology

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

2022

Confirm

Do you wish to request the book?

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Morschhauser, Franck,

Kwong, Yok-Lam,

Müller, Antonia M.S,

Dreyling, Martin,

Bachy, Emmanuel,

Masood, Aisha,

Holte, Harald,

del Corral, Christopher,

Degtyarev, Evgeny,

Bishop, Michael R,

Le Gouill, Steven,

Kersten, Marie J,

Kharfan-Dabaja, Mohamed,

Greil, Richard,

Chan, Esther H.L,

Martinez-Lopez, Joaquin,

Bond, David,

Hamad, Nada,

Sureda, Anna,

Barba, Pere,

Rabitsch, Werner,

Kato, Koji,

Borchmann, Peter,

Awasthi, Rakesh,

Westin, Jason R,

Janz, Martin,

Harigae, Hideo,

McSweeney, Peter,

Santoro, Armando,

Minnema, Monique C,

Thieblemont, Catherine,

Maziarz, Richard T,

McGuirk, Joseph P,

Andreola, Giovanna,

Flinn, Ian,

Schuster, Stephen J,

Andreadis, Charalambos,

Newsome, Simon,

Jäger, Ulrich,

Dickinson, Michael,

Purtill, Duncan

2022

Overview

A randomized trial comparing the CD19-specific CAR T-cell therapy tisagenlecleucel with salvage chemotherapy followed by high-dose therapy and autologous hematopoietic stem-cell transplantation in patients with refractory or early relapsed aggressive B-cell lymphoma did not show a longer event-free survival with CAR T cells.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Agents, Immunological - therapeutic use

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Autografts